COGT — Cogent Biosciences Cashflow Statement
0.000.00%
Last trade - 00:00
- $1.16bn
- $800.24m
- 43
- 18
- 86
- 47
2019 December 31st | 2020 December 31st | 2021 December 31st | 2022 December 31st | 2023 December 31st | |
---|---|---|---|---|---|
Period Length: | 12 M | 12 M | 12 M | 12 M | 12 M |
Source: | 10-K | 10-K | 10-K | 10-K | 10-K |
Standards: | USG | USG | USG | USG | USG |
Status: | Final | Final | Final | Final | Final |
Net Income/Starting Line | -31.8 | -74.8 | -72.3 | -140 | -192 |
Depreciation | |||||
Non-Cash Items | 3.11 | 43.6 | 11.3 | 20 | 25.1 |
Unusual Items | |||||
Other Non-Cash Items | |||||
Changes in Working Capital | -14.1 | -5.32 | 2.02 | 0.751 | 11.4 |
Change in Accounts Receivable | |||||
Change in Prepaid Expenses | |||||
Change in Other Assets | |||||
Change in Accounts Payable | |||||
Change in Accrued Expenses | |||||
Change in Other Liabilities | |||||
Cash from Operating Activities | -41.5 | -35.9 | -58.8 | -119 | -154 |
Capital Expenditures | -0.033 | 0 | -1.72 | -6.86 | -2.8 |
Purchase of Fixed Assets | |||||
Other Investing Cash Flow Items | 23.2 | 8.42 | 0 | -118 | -95 |
Sale of Business | |||||
Sale of Fixed Assets | |||||
Sale/Maturity of Investment | |||||
Purchase of Investments | |||||
Cash from Investing Activities | 23.2 | 8.42 | -1.72 | -125 | -97.8 |
Financing Cash Flow Items | — | — | -0.085 | 0 | 0 |
Other Financing Cash Flow | |||||
Net Issuance / Retirement of Stock | |||||
Cash from Financing Activities | 0.108 | 232 | 38 | 164 | 164 |
Beginning Cash Balance | |||||
Ending Cash Balance | |||||
Net Change in Cash | -18.2 | 205 | -22.5 | -79.8 | -87.9 |